UNIVERSAL-BEAUTY
9.12.2021 19:17:05 CET | Business Wire | Press release
The French natural cosmetics company, known for its Végétalement Provence brand, announces a €6m capital raise from a group of investors led by Connect Pro, an investment fund based in Marseille.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211209005914/en/
New shareholders
The arrival of new investors to develop Végétalement Provence, is led by Connect Pro alongside the private equity funds BNP Paribas Développement and Etoile Capital, whose membership of leading banking groups, will ensure the sustainability of the support. The financing is completed by the Région Sud Investissement fund.
« We were won over by the commitment and geographic proximity of Connect Pro and its co-investors, to help companies of our region to grow in France and internationally».
Vincent Faraco,
Co-Founder of Universal Beauty Group
Following the transaction, the founders, Vincent Faraco and Jean-Marc Delabre, will remain reference shareholders and will continue to lead the group.
« We are proud to invest in Universal Beauty Group, which will be the first investment of our new Sud Rebound fund launched in June this year. This venture in the heart of the local economic ecosystem is fully in line with our strategy to support the development of key business in our region».
Franck Paoli,
President and Founder of Connect Pro
Partners in growth
The investors’ entry into the company’s capital will allow the business to accelerate its development in the rapidly expanding natural beauty sector, a market expected to show annual growth of 6-9% over the period 2021-2027.
This transaction follows the first investment in the company’s capital in 2017 made by the private-equity fund Audacia, whose support has made it possible to double the number of product references and open 3 own-brand concept salons alongside about twenty independent concept salons under the Végétalement Provence brand, including the most recent salon opened in Lyon in October.
Végétalement Provence – a committed beauty brand
In 2008, Universal Beauty Group started as a distributor of haircare brands before launching its own brand Végétalement Provence in 2011 to offer hairdressing professionals a technical product that was kinder to the environment and customers’ health. In the space of a few years, Végétalement Provence has become a premium beauty brand recognized as much by professionals as by a general public in search of wellness.
With 170,000 products sold in 2020, Universal Beauty Group forecasts sales of €4m in 2021, with an EBITDA margin of around 20%. 70% of sales are made in mainland France, 15% in the French island of Reunion, and 15% internationally. Its eco-responsible products have been rewarded with numerous prizes for their innovation, and are acclaimed by international colourists and hair stylists in search of natural and high-performance products. The brand is distributed via more than 500 points of sale and through its own e-shop.
Established in Saint-Rémy-de-Provence in the South of France since 2014, Universal Beauty Group, with the support of its teams, training academy, and logistics base, is ready to become a major player in alternative cosmetics and beauty.
« We are delighted to welcome our new partners who will bring their vision and support to the growth of Végétalement Provence whose potential is limitless ».
Jean-Marc Delabre,
Co-Founder of Universal Beauty Group
Among the projects for Végétalement Provence
The product range, designed and developed in Saint-Rémy-de-Provence will be further expanded. With the support of its new investor base focused on the region, Universal Beauty will place a particular emphasis on innovation
The company also plans to open a concept store in Paris in Spring 2022, a new base for Végétalement Provence. A significant investment will be dedicated to the digital development of the brand and to support e-commerce. Previously centred more on its domestic market, the new round of financing will allow the company to consolidate its international expansion.
"We are delighted to accompany the leaders of Végétalement Provence in this great adventure. With its unique products, Végétalement Provence responds to a fundamental trend. The increase in the number of people looking for natural products continues to grow and will offer significant development opportunities."
Rémy Garello,
Managing Director of Connect Pro
Fundraising process
The transaction is the conclusion of a competitive process launched in May 2021 to search for an investor. The process attracted very strong interest both in France and abroad from haircare and beauty companies, as well as private equity and family offices.
Universal Beauty Group was advised by Richard Morgan Advisory (Richard Morgan) and the law firm Volt Associés (Stéphane Letranchant, Lucas d'Orgeval). The investors were advised by the law firm Nova Partners (Olivier Nett, Julien Immoff), with the financial audit carried out by Deloitte Finance (Thomas Gorguis).
Universal Beauty Group - Végétalement Provence
Since its launch in 2011, with its hair and skincare ranges, Végétalement Provence quickly established itself as a real alternative to major brands among hairdressers and beauty professionals.
Its efficient plant-based product ranges, with natural and organic sourcing, meet the needs of a demanding professional public looking for technical prowess with a philosophy of eco-responsibility. In addition to the attractiveness and performance of its products, Universal Beauty Group benefits from a network of professional customers whose resale rate of Végétalement Provence products is unparalleled. While the usual resale rate of the sector in France is around 5%, it exceeds 20% with Végétalement Provence.
Today the brand offers a range of over 275 different beauty product references including 140 in hair and skincare for the general public, covering all needs.
Its ranges combine not just beauty and health, but also wellness based on the foundation of innovation and commitment.
The development of creative styling products, and the introduction of a specific line for ethnic hair, complete the product range. The Essentiels collection, with its shampoos and conditioners, has become a must-have for lovers of the brand.
For its professional clientele, Végétalement Provence offers a range of more than 130 colouring references, with an offer by oxidation and an organic offer based on plant powder.
Végétalement Provence currently has about twenty employees in its Saint-Rémy-de-Provence headquarters.
Connect Pro
Since its creation in 2007, Connect Pro has been supporting small and midcap businesses in the South of France in their development and transmission needs with more than €70m in capital invested. Among the latest equity investments, Mariton designs, manufacturer and distributer of custom-made mosquito nets and interior blinds, EITP, a heating and air-conditioning company and Pharma Santé Développement, a group of independent pharmacies. With Sud Rebond, Connect Pro launched its third fund in June 2021 with a fundraising of more than €15m from institutional investors and entrepreneurs in the South-East of France. It will be completed by a second round of fundraising in the first half of 2022 to reach €25m.
BNP Paribas Développement
One of the private equity funds of the BNP Paribas banking group, BNP Paribas Développement, manages €1 billion of its own funds, investing directly to support the development of successful mid-sized companies. BNP Paribas Développement, whose mission is to support management teams in the realization of medium-term strategic projects, has a portfolio of more than 400 holdings.
www.bnpparibasdeveloppement.com
Etoile Capital
Etoile Capital, a subsidiary of the bank Crédit du Nord, is a shareholder of French small business in widely diversified sectors, with a portfolio currently of about twenty investments. It positions itself as a shareholder in the capital of corporate clients of the various regional banks that make up the Crédit du Nord group. The fund brings to the shareholders and managers of its invested companies its expertise in strategic thinking and the means to accelerate development.
www.corporatefinance.groupe-credit-du-nord.fr
Région Sud Investissement
Région Sud Investissement is the regional investment company created in 2010 by the Southern Region of France to support the emergence and development of high growth companies.
Région Sud Investissement, endowed with €134m, benefits from the support of the European Union through the ERDF (European Regional Development Fund), which contributes 42% of its funding. Région Sud Investissement is advised by Turenne Groupe in the management of its holdings.
www.regionsudinvestissement.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20211209005914/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
